Taysha IPO Presentation Deck

Offering Summary Issuer Ticker/ Exchange Base Offering Size Overallotment option Filing range Use of proceeds Bookrunners Manager Expected pricing Lock up Taysha Gene Therapies, Inc. TSHA / Nasdaq Global Market 6,578,950 shares (~$125 million gross proceeds based on midpoint of the range, 100% primary) 986,842 shares (100% primary, 15% of base deal) $18.00-$20.00 per share Fund discovery and IND-enabling activities, manufacturing and quality control testing for the clinical programs and preclinical programs in the IND-enabling stage in the pipeline Clinical trial, regulatory and medical activities for TSHA-101, TSHA-102, TSHA-103, TSHA-104 and TSHA-118 Establishment of an in-house manufacturing facility A portion of the proceeds of the remaining net proceeds may also be used to in-license, acquire or invest in complementary businesses, technologies, products or assets The remainder for working capital and other general corporate purposes Goldman Sachs & Co. LLC, Morgan Stanley, Jefferies Chardan September 23, 2020 180 days for the Company's directors, executive officers and substantially all existing security holders 3

View entire presentation